Form 4: GE HealthCare CEO Kevin O'Neill Reports Stock Transactions
SEC Form 4 Filing
CEO Kevin O'Neill reports acquisition and disposal of GE HealthCare Technologies Inc. stock and stock options.
Summary
- Kevin Michael O'Neill, CEO of GE HealthCare Technologies Inc., filed a Form 4 detailing changes in beneficial ownership.
- On March 1, 2025, 1,521 shares of common stock were withheld to satisfy tax obligations at a price of $87.35 per share.
- On March 3, 2025, O'Neill acquired 4,626 restricted stock units (RSUs) and 13,231 employee stock options.
- The RSUs vest in three tranches: 33% on September 3, 2026, 33% on September 3, 2027, and 34% on September 3, 2028.
- The employee stock options also vest in three tranches, becoming exercisable on the same dates as the RSUs, with an exercise price of $86.45.
- Following these transactions, O'Neill directly owns 22,980 shares of common stock and indirectly owns 59 shares through a share incentive plan trust.
- O'Neill also holds options to purchase 13,231 shares.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine filing of stock transactions. The grants suggest confidence, but the tax withholding is a standard procedure.
Positives
- The award of restricted stock units and employee stock options to the CEO aligns his interests with the long-term performance of the company.
- The vesting schedule of the RSUs and stock options encourages long-term commitment from the CEO.
Future Outlook
The document does not contain specific forward-looking statements, but the vesting schedule of the RSUs and stock options suggests a long-term commitment from the CEO.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's confidence in the company's future prospects.
Comparison to Industry Standards
- Stock option and RSU grants are a common form of executive compensation in the healthcare technology industry.
- Vesting schedules of three years are typical to incentivize long-term performance.
- The size of the grant is relative to the executive's role and the company's overall compensation strategy; benchmarking against peers like Siemens Healthineers or Philips would provide further context.
Stakeholder Impact
- The transactions have a minor impact on shareholders, as they reflect changes in the CEO's ownership stake.
- Employees may be indirectly affected by the CEO's incentives being aligned with the company's long-term success.
Key Dates
| Date | Description |
|---|---|
| 03/01/2025 | Withholding of 1,521 shares for tax obligations. |
| 03/03/2025 | Award of 4,626 restricted stock units and 13,231 employee stock options. |
| 03/05/2025 | Date of Form 4 filing. |
| 09/03/2026 | First vesting date for 33% of RSUs and stock options. |
| 09/03/2027 | Second vesting date for 33% of RSUs and stock options. |
| 09/03/2028 | Final vesting date for 34% of RSUs and stock options. |
| 03/03/2035 | Expiration date of employee stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.